Introduction to Hemp Industry Regulation and Rescheduling
The landscape of hemp industry regulation is undergoing significant shifts, influenced by recent legislative actions and the federal rescheduling of certain cannabis products. While the 2018 Farm Bill initially carved out a legal pathway for industrial hemp, subsequent developments have introduced new complexities for operators. The recent order by the Drug Enforcement Administration (DEA) to move specific marijuana products from Schedule I to Schedule III of the Controlled Substances Act does not directly alter the classification of hemp, but it signals potential changes in the broader regulatory environment for cannabinoids.
The Agriculture Bill and Hemp’s Current Status
A critical development for the hemp industry was the passage of the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2026, referred to as the “Agriculture Bill,” in 2025. This legislation redefined hemp at the federal level. Effective November 12, 2026, the new law mandates that finished hemp products be capped at a maximum of 0.4 milligrams of total THC per container, moving beyond the previous delta-9 THC dry weight basis measurement. Industry estimates suggest this provision could affect a significant portion of currently marketed hemp-derived consumer products.
This redefinition means that many products currently in the “Farm Bill hemp gray area”—such as delta-8, delta-10, and THCA flower—could fall under the definition of marijuana in the Controlled Substances Act once the new law takes effect. Enforcement of these new provisions is slated to begin in November 2026, prompting industry stakeholders to monitor potential legislative relief.
Cannabis Rescheduling: Direct vs. Indirect Effects on Hemp
The Department of Justice’s (DOJ) final order rescheduling two classes of marijuana—specifically FDA-approved marijuana products and marijuana subject to a state medical marijuana license—from Schedule I to Schedule III, does not directly impact hemp’s classification. Hemp was removed from the Controlled Substances Act by the 2018 Farm Bill, and this status remains unchanged by the rescheduling order.
However, the rescheduling does carry indirect implications for hemp industry regulation. The DOJ’s order, by endorsing state medical marijuana program frameworks and acknowledging a consumer market for cannabinoids under appropriate regulatory oversight, sends a signal. This framing aligns with arguments from the hemp industry that regulated access to CBD and other hemp-derived products serves legitimate consumer needs and warrants a coherent federal framework rather than restrictive bans.
Political Signals and Legislative Avenues
Political discourse surrounding hemp has also intensified. On April 23, the day before the DOJ formally announced the rescheduling order, President Trump posted on Truth Social, advocating for congressional action to protect access to full-spectrum CBD products. He referenced his December executive order directing research and innovation on hemp-derived CBD and noted a pilot program by Dr. Mehmet Oz at the Centers for Medicare & Medicaid Services (CMS) allowing some Medicare beneficiaries access to hemp-derived CBD products. While the President signed the Agriculture Bill, his public statements indicate a preference for legislative adjustments to preserve access to full-spectrum CBD while addressing products posing health risks.
Key Areas for Hemp Operators to Monitor:
- Farm Bill Reauthorization: The 2018 Farm Bill requires reauthorization by September 30, 2026, preceding the November hemp product ban. This legislative vehicle is considered the most realistic opportunity to modify the Agriculture Bill’s hemp provisions, with advocates pushing for amendments to revert broad product restrictions while maintaining bans on synthetic and clearly intoxicating cannabinoids.
- Congressional Fixes: Several bills, including the Hemp Planting Predictability Act, have been introduced to delay or modify the November ban. Senator Rand Paul has been a vocal critic of the ban, and the President’s public statements may generate political momentum for a legislative solution, particularly in agricultural states.
- CMS Pilot Program and FDA Posture: The administration’s implementation of a model for Medicare coverage of hemp-derived CBD, with up to $500 in annual coverage for eligible beneficiaries, and the FDA’s stated non-interference with this program, establish a real-world precedent for regulated CBD access. Operators should monitor this program’s impact.
- June 29 Rescheduling Hearing: A new DOJ hearing beginning June 29, to consider broader marijuana rescheduling, will generate a record on the potential benefits and regulatory frameworks for cannabinoids. Arguments presented in this hearing regarding consumer access, safety, and regulatory structures will be relevant to the ongoing CBD policy debate.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
